Canakinumab (ACZ885) for treatment and prevention of gout flares
Gouty Arthritis
Enrolment: 136 · Results not recorded
Loading the evidence…
Biologic · Drug-class entry: no specific agent named in the source abstract, so resolved=false. The canonical clinical anti-IL-1beta antibody is canakinumab (ChEMBL CHEMBL1201834, antibody, approved 2009, ATC L04AC08, Ilaris/ACZ885); gevokizumab is a second class member. Trials below are class-level canakinumab studies, INDIRECT evidence only.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Gouty Arthritis
Enrolment: 136 · Results not recorded
Peripheral Artery Disease
Enrolment: 38 · Results not recorded
Knee Osteoarthritis
Enrolment: 23 · Results not recorded
Schnitzler Syndrome
Enrolment: 1 · Results not recorded
Arthritis, Juvenile Rheumatoid
Enrolment: 26 · Results not recorded
Wet Age-Related Macular Degeneration
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute liver injury induced by intravenous injection of the fungal lectin Agrocybe aegerita galectin (AAGL), compared with the concanavalin A model
Intravenous AAGL induced infiltration and activation of T, NKT and NK cells in the liver, with T cells central to the pathogenesis. IL-1beta was expressed far more highly in AAGL-treated than concanavalin A-treated mice, and anti-IL-1beta ameliorated AAGL-induced liver injury by inhibiting NF-kappa…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.